| Assessment Status | Rapid Review Complete |
| HTA ID | 23038 |
| Drug | Beclometasone/formoterol |
| Brand | Fostair® |
| Indication | Beclometasone/formoterol (Fostair®) is indicated for the regular treatment of asthma where use of a combination product (inhaled corticosteroid [ICS] and long-acting beta2-agonist [LABA]) is appropriate: -in patients not adequately controlled with ICS and 'as needed' inhaled rapid-acting beta2-agonist; or -in patients already adequately controlled on both ICS and LABA. |
| Assessment Process | |
| Rapid review commissioned | 10/07/2023 |
| Rapid review completed | 20/07/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that Fostair® for this indication not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.